Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm

The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Charlie, Brezden-Masley, Christine, Joy, Anil Abraham, Sehdev, Sandeep, Modi, Shanu, Simmons, Christine, Henning, Jan-Willem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262633/
https://www.ncbi.nlm.nih.gov/pubmed/37323186
http://dx.doi.org/10.1177/17588359231175440
Descripción
Sumario:The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival benefit among patients with hormone receptor-positive and hormone receptor-negative disease and low expression of HER2, a biomarker previously considered unactionable in this treatment setting. Herein, we discuss the evolving therapeutic pathway for HER2-low disease, ongoing clinical trials, and the potential challenges and evidence gaps arising with treatment of this patient population.

Ejemplares similares